The Yorkville convertible note is a classic 'death spiral' structure — variable conversion at a discount to market — which will create persistent downward selling pressure as the holder converts and sells shares. Monitor daily volume and share price for conversion activity. The company's cash runway remains very limited ($4.655M net) for a pre-revenue biotech, making additional dilutive financings likely. Short interest of 70M shares suggests the market is already positioned for this outcome.
Price Chart
Executive Summary
Northwest Biotherapeutics filed a 424B5 prospectus supplement to register 40,325,000 shares of common stock, primarily related to a $4.9 million convertible promissory note financing with Yorkville Advisors (YA II PN, Ltd.) entered into on July 29, 2026. The offering is dilutive at a price of $0.16 per share (the market close on July 29), with net proceeds of approximately $4.655 million for general corporate purposes. This is the company's fifth offering/registration filing in the last 24 months, continuing a pattern of dilutive financing for a pre-revenue clinical-stage biotech with a negative tangible book value of $(90.7) million.
Key Facts
- $4.9 million convertible promissory note financing with YA II PN, Ltd. (Yorkville Advisors) entered on July 29, 2026.
- Registration of 30,625,000 reserve shares at $0.16/share for potential conversion of the Note, plus 9,700,000 warrant shares at $0.205/share.
- Net proceeds estimated at $4,655,000 after OID and expenses.
- Pro forma shares outstanding after offering: 1,733,922,187, up from 1,693,597,187 as of July 30, 2026.
- Net tangible book value as of March 31, 2026 was $(90.7) million, or $(0.06) per share; after offering, $(84.1) million, or $(0.05) per share.
- Note is 12-month term, 5% OID, no interest, convertible at a discount to market price — a toxic convertible structure.
- This is the 5th offering/registration filing in 24 months, indicating persistent cash needs.
Financial Impact
Dilutive offering of up to 40,325,000 shares at $0.16/share, raising $4.655 million net. Existing shareholders face ~2.4% dilution from this tranche alone, with further dilution from the variable-rate convertible note structure.
Risk Factors
- Persistent dilution from the variable-rate convertible note conversion at a discount to market price.
- Limited cash runway of ~$4.655M for a pre-revenue clinical-stage biotech with ongoing R&D and regulatory costs.
- Pattern of repeated dilutive financings (5 in 24 months) suggests inability to secure non-dilutive capital.
- Going concern risk highlighted in the auditor's report (incorporated by reference).
- OTCQB listing with high short interest (70M shares) indicates weak institutional support.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001104659-26-089290 |
| Document: 0001104659-26-089290-index-headers.html | 0001104659-26-089290 |
| Document: 0001104659-26-089290-index.html | 0001104659-26-089290 |
| Document: 0001104659-26-089290.txt | 0001104659-26-089290 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 31, 2026 12w ago | 424B5 | $0.1600 $0.1700 | ▼ −6.25% | ▼ −5.01% | $0.1650 (−3.13%) |
Apr 21, 2026 27w ago | EFFECT | $0.1900 $0.2500 | ▲ +31.58% | ▲ +26.66% | $0.1650 (−13.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers